NeoGenomics, Inc. NEO
16.83 USD -0.13 (-0.77%)
At closeNov 12, 2026, 4:19 AM EST
16.90 +0.07 +0.42%
Pre-market · Nov 12, 4:19 AM ET
16.75 Day range 17.67
7.07 52-week range 20.15
- YTD
- +43.11%
- 1 year
- +68.30%
News
globenewswire.com FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track DENVER, Nov. 11, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews ) — NeOnc Technologies Holdings (NASDAQ: NTHI) secured a Type B End-of-Phase meeting, scheduled for early January 2027, with the U.S. Food…
globenewswire.com NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100 CALABASAS, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for…
defenseworld.net Neo Performance Materials Q3 Earnings Call Highlights Neo Performance Materials (TSE: NEO) raised its full-year 2026 earnings outlook after reporting a sharp increase in third-quarter revenue and adjusted earnings, as demand and pricing strengthened…
businesswire.com NeoGenomics to Participate in Upcoming Investor Conferences FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Stephens Annual Investment Conference and the Piper Sandler 38th Annual Healthcare Conference.
benzinga.com TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $23 TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $19 to $23.
benzinga.com NeoGenomics Q3 2026 Earnings Call Transcript NeoGenomics (NASDAQ:NEO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…
benzinga.com NeoGenomics Raises FY2026 Sales Guidance from $802.000M-$806.000M to $807.000M-$809.000M vs $805.827M Est NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $802.000 million-$806.000 million to $807.000 million-$809.000 million vs $805.827 million estimate.
benzinga.com NeoGenomics Q3 Adj. EPS $0.07 Beats $0.05 Estimate, Sales $209.254M Beat $207.328M Estimate NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.05 by 40 percent. This is a 133.33 percent increase over earnings of $0.03 per…